Treatment-related vitiligo is sometimes observed in patients with melanoma1 and is associated with a good clinical response to anti–PD-1 (programmed cell death 1 protein) antibodies.2-4 Although cellular and humoral immune responses may be key factors for vitiligo occurrence, data on reduced immune responses in association with vitiligo repigmentation are lacking in patients with melanoma. We report a rare case of metastatic melanoma with a complete response and simultaneous vitiligo during nivolumab therapy. To our knowledge, vitiligo repigmentation developing in association with tumor relapse has not been reported previously.
Nakamura Y, Teramoto Y, Asami Y, et al. Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma. JAMA Dermatol. 2017;153(9):942–944. doi:10.1001/jamadermatol.2017.1679
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: